25-hydroxy-vitamin D metabolism in human colon cancer cells during tumor progression

被引:104
作者
Bareis, P
Bises, G
Bischof, MG
Cross, HS
Peterlik, M
机构
[1] Univ Vienna, Sch Med, Dept Pathophysiol, A-1090 Vienna, Austria
[2] Univ Vienna, Sch Med, Clin Internal Med 3, Div Endocrinol & Metab, A-1090 Vienna, Austria
关键词
1; alpha; 25-dihydroxyvitamin D-3; large intestine; adenocarcinoma; primary culture; vitamin D metabolism; side-chain oxidation; vitamin D-1 alpha-hydroxylase; CYP; vitamin D-24-hydroxylase; 24;
D O I
10.1006/bbrc.2001.5289
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RT-PCR analysis showed elevated expression of 25-hydroxyvitamin D1 alphaa-hydroxylase (1 alpha -OHase) and of 25-hydroxyvitamin D-24-hydroxylase (24-OHase) in well differentiated human colon carcinomas in comparison to normal mucosa. Further tumor progression is associated with a rise in 1 alpha -OHase but with no significant change in 24-OHase mRNA expression. Accordingly, HPLC analysis of 25-hydroxy-vitamin D-3 metabolism mi freshly isolated tumor cells indicated that well to moderately differentiated colon cancers in situ are able to produce 1 alpha ,25-dihydroxyvitamin D-3 (1 alpha ,25-(OH)(2)D-3) and convert it through 24-OHase activity into side-chain modified metabolites, 1,24,25-(OH)(3)-D-3 and 1,25-(OH)(2)-24-oxo-D-3. Likewise, 25-(OH)-D-3 is metabolized into 24,25-(OH)(2)D-3, 23,25-(OH)(2)D-3, and 23,25-(OH)(2)-24-oxo-D-3. Poorly-differentiated cancers expressed low levels of 1 alpha -OHase mRNA, whereas 24-OHase was even overexpressed. RT-PCR and HPLC analysis of vitamin D metabolism in primary culture cell clones strongly suggested that the extent of endogenously produced 1 alpha ,25(OH)(2)-D-3 was inversely related to 24-OHase activity, which could thus limit the antimitotic efficacy of la,25(OH)2-D3 particularly at late stages of colon cancer progression. (C) 2001 Academic Press.
引用
收藏
页码:1012 / 1017
页数:6
相关论文
共 21 条
  • [1] Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene
    Albertson, DG
    Ylstra, B
    Segraves, R
    Collins, C
    Dairkee, SH
    Kowbel, D
    Kuo, WL
    Gray, JW
    Pinkel, D
    [J]. NATURE GENETICS, 2000, 25 (02) : 144 - 146
  • [2] [Anonymous], 1992, TNM classification of malignant tumors
  • [3] Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme
    Beckman, MJ
    Tadikonda, P
    Werner, E
    Prahl, J
    Yamada, S
    DeLuca, HF
    [J]. BIOCHEMISTRY, 1996, 35 (25) : 8465 - 8472
  • [4] Differentiation-related pathways of 1α,25-dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells:: Production of 1α,25-dihydroxy-3epi-cholecalciferol
    Bischof, MG
    Siu-Caldera, ML
    Weiskopf, A
    Vouros, P
    Cross, HS
    Peterlik, M
    Reddy, GS
    [J]. EXPERIMENTAL CELL RESEARCH, 1998, 241 (01) : 194 - 201
  • [5] Bischof MG, 1995, J PHARMACOL EXP THER, V275, P1254
  • [6] GROWTH-CONTROL OF HUMAN COLON CANCER-CELLS BY VITAMIN-D AND CALCIUM INVITRO
    CROSS, HS
    PAVELKA, M
    SLAVIK, J
    PETERLIK, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (17): : 1355 - 1357
  • [7] 25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis
    Cross, HS
    Bareis, P
    Hofer, H
    Bischof, MG
    Bajna, E
    Kriwanek, S
    Bonner, E
    Peterlik, M
    [J]. STEROIDS, 2001, 66 (3-5) : 287 - 292
  • [8] Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: Expression of 25-hydroxyvitamin D-3-1 alpha-hydroxylase activity and regulation of side-chain metabolism
    Cross, HS
    Peterlik, M
    Reddy, GS
    Schuster, I
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1997, 62 (01) : 21 - 28
  • [9] CROSS HS, 1993, N-S ARCH PHARMACOL, V347, P105
  • [10] Hofer H, 1999, J PHARMACOL EXP THER, V291, P450